CN106418542A - Health-care product having function of regulating blood lipids and preparation method thereof - Google Patents
Health-care product having function of regulating blood lipids and preparation method thereof Download PDFInfo
- Publication number
- CN106418542A CN106418542A CN201610851226.1A CN201610851226A CN106418542A CN 106418542 A CN106418542 A CN 106418542A CN 201610851226 A CN201610851226 A CN 201610851226A CN 106418542 A CN106418542 A CN 106418542A
- Authority
- CN
- China
- Prior art keywords
- oil
- health
- care
- regulating blood
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 103
- 239000008280 blood Substances 0.000 title claims abstract description 103
- 150000002632 lipids Chemical class 0.000 title claims abstract description 73
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 235000019198 oils Nutrition 0.000 claims abstract description 197
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 32
- 229930195729 fatty acid Natural products 0.000 claims abstract description 32
- 239000000194 fatty acid Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 30
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 3
- 230000036541 health Effects 0.000 claims description 141
- 230000009471 action Effects 0.000 claims description 65
- 244000124853 Perilla frutescens Species 0.000 claims description 45
- 235000004347 Perilla Nutrition 0.000 claims description 44
- 150000004665 fatty acids Chemical class 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 27
- 230000001804 emulsifying effect Effects 0.000 claims description 26
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 22
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 22
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 22
- 239000008346 aqueous phase Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 17
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 17
- 235000021324 borage oil Nutrition 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 235000002378 plant sterols Nutrition 0.000 claims description 14
- 235000009811 Momordica charantia Nutrition 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 13
- 238000005253 cladding Methods 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 238000005507 spraying Methods 0.000 claims description 13
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 10
- 239000000419 plant extract Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 244000078912 Trichosanthes cucumerina Species 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000003921 oil Substances 0.000 abstract description 182
- 239000000047 product Substances 0.000 abstract description 94
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 31
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 18
- 229960004488 linolenic acid Drugs 0.000 abstract description 18
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 15
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 15
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 abstract description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 11
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 abstract description 11
- 235000020664 gamma-linolenic acid Nutrition 0.000 abstract description 11
- 229960002733 gamolenic acid Drugs 0.000 abstract description 11
- 235000020778 linoleic acid Nutrition 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 10
- 244000294611 Punica granatum Species 0.000 abstract description 4
- 235000014360 Punica granatum Nutrition 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 235000007689 Borago officinalis Nutrition 0.000 abstract description 3
- 235000004496 Oenothera biennis Nutrition 0.000 abstract description 3
- 240000008916 Oenothera biennis Species 0.000 abstract description 2
- -1 compound fatty acid Chemical class 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 229940045761 evening primrose extract Drugs 0.000 abstract description 2
- 235000008524 evening primrose extract Nutrition 0.000 abstract description 2
- 240000004355 Borago officinalis Species 0.000 abstract 1
- 240000002547 Rosa roxburghii Species 0.000 abstract 1
- 235000000640 Rosa roxburghii Nutrition 0.000 abstract 1
- 229940018006 basil oil Drugs 0.000 abstract 1
- 239000010619 basil oil Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 229940098330 gamma linoleic acid Drugs 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 39
- 235000019197 fats Nutrition 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 13
- 239000005913 Maltodextrin Substances 0.000 description 12
- 229920002774 Maltodextrin Polymers 0.000 description 12
- 244000302512 Momordica charantia Species 0.000 description 12
- 229940035034 maltodextrin Drugs 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 235000014593 oils and fats Nutrition 0.000 description 7
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108010003541 Platelet Activating Factor Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 240000008415 Lactuca sativa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000003516 hyperlipidaemic effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241001072256 Boraginaceae Species 0.000 description 2
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000208202 Linaceae Species 0.000 description 2
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 2
- 241000219925 Oenothera Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000968928 Carex brizoides Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005097 cold rolling Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000036035 hypolipemia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a health-care product having a function of regulating blood lipids and belongs to the field of health-care products. The health-care product having the function of regulating blood lipids comprises the following materials in parts by weight: 17-70 parts of health-care oil and 10-40 parts of rosa roxburghii seed oil; wherein the health-care oil at least comprises two of basil oil, linseed oil, oenothera biennis oil, borago officinalis oil, and pomegranate seed oil. In the provided recipe of the health-care products, the ratios of alpha-linolenic acid, gamma-linolenic acid and linoleic acid can meet the requirements of nutritional supplements by human body, which is conductive to application of the product in supplementing various unsaturated fatty acids and preventing cardiovascular and cerebrovascular diseases. Besides, the present invention also provides the preparation method of the health-care product having the function of regulating blood lipids and a method of preparing the health-care products into compound fatty acid powder. The preparation method can improve the stability and liquidity of the health-care compound oil, can be combined with other functional powders, expands the dosage forms, enhances the efficacy, and meets the requirements of different populations.
Description
Technical field
The present invention relates to a kind of field of health care products, and particularly to a kind of health product with regulating blood lipid action and its system
Preparation Method.
Background technology
In global range, 18% cardiovascular disease and 56% ischemic heart desease be all by hypercholesterolemia directly or
Connect and cause.Occidentals's cholesterol levels of 50-60% are exceeded.In the world every year because the number of the death with high fat of blood reaches
2600000.The main harm that cholesterolemia concentration raises is easily to cause atherosclerosiss and coronary heart disease.It is now recognized that reduction serum
Cholesterol levels are coronary heart disease preventing and treating most effectively one of measures.
In China, 2002, China coronary death toll, more than 700,000 people, was only second to India, positioned at the whole world second.In
State's Ministry of Public Health Women health questionnaire in 2004 is bright：China's hyperlipemic patients are up to 1.6 hundred million people, hyperpietic 1.6 hundred million people, adult body
The exceeded person of weight 22%.According to scholarly forecast, the mean total cholesterol in Asia often rises 1mmol/L, because the death that coronary heart disease leads to is several
Rate will increase by 35%.According to WHO2000, between 1984 to 1999, the horizontal male of Beijing mean total cholesterol
5.25mmol/L is increased to by 4.15mmol/L, women rises to 5.10mmol/L by 4.17mmol/l.Therefore in daily life
In, supplement some in good time and there is the health food of auxiliary lipid-lowering function, the generation of hyperlipemia can be prevented.
Numerous studies show both at home and abroad, and unsaturated fatty acid can make cholesterol be esterified, and reduces blood cholesterol and glycerol
Three esters, thus play effect of blood-fat-decreasing.In order to reach the optimal lipid-lowering effect of unsaturated fatty acid, researchers
By the mixing of the unsaturated fatty acid of n-3 and n-6 two series, wherein n-3 series unsaturated fatty acid mainly comprise alpha-linolenic acid,
EPA, DHA, n-6 series unsaturated fatty acid mainly comprises gamma-Linolenic acid, linoleic acid etc..But it is contained in majority of plants
Linoleic acid, gamma-Linolenic acid, alpha-linolenic acid etc. be all unbalanced.Scientific investigations showed that, n-6：Total absorption of n-3 two series
Amount should have certain proportion, the proposed standard that Chinese Soclety of Nutrition is formulated for 2000, n-6:N-3=4-6:1.Therefore according to feelings
Condition, the polyunsaturated fatty acid taking in suitable proportioning is extremely important, and existing edible oil or health-care oil can not reach
This purpose.
Content of the invention
It is an object of the invention to provide a kind of health product with regulating blood lipid action, alpha-linolenic acid, γ-Asia in product
Fiber crops acid and linoleic acid proportioning can reach suitable proportioning, particularly can make unsaturated fatty acid n-6：N-3 reaches 4:1.
Another object of the present invention is to providing a kind of preparation method of the health product with regulating blood lipid action, can subtract
Unsaturated fatty acid in few course of processing decomposes and runs off, and improves stability, the mobility of product simultaneously, expands product
Dosage form is so as to can compound with multiple efficacies pressed powder to strengthen effect.
Present invention also offers a kind of application on health food for above-mentioned health product with regulating blood lipid action, can make
The health food of standby one-tenth prevention cardiovascular and cerebrovascular disease.
The present invention solves its technical problem and employs the following technical solutions to realize.
The present invention proposes a kind of health product with regulating blood lipid action, counts by weight, it includes：17-70 part is protected
Strong oil and 10-40 part Fructus Rosae Normalis seed oil；Wherein, health-care oil includes perilla oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, Punica granatum L.
In seed oil at least two.
Further, in present pre-ferred embodiments, count by weight, there is the health product bag of regulating blood lipid action
Include：5-10 part perilla oil, 12-60 part Radix Oenotherae erythrosepalae oil and 10-40 part Fructus Rosae Normalis seed oil.
Further, in present pre-ferred embodiments, the health product with regulating blood lipid action also include 3-6 part plant
Extract, plant extract includes Ginkgo Biloba Extract, bitter gourd polypeptide, at least one in oat peptide.
Further, in present pre-ferred embodiments, count by weight, there is the health product bag of regulating blood lipid action
Include：5-10 part perilla oil, 12-60 part Radix Oenotherae erythrosepalae oil, 10-40 part Fructus Rosae Normalis seed oil, 1-3 part oat peptide, 1-3 part bitter gourd polypeptide and
1-3 part Ginkgo Biloba Extract.
Further, in present pre-ferred embodiments, count by weight, there are the health product of regulating blood lipid action also
Including 1-3 part phospholipid additive, phospholipid additive includes at least one in Phosphatidylserine and plant sterol.
Further, in present pre-ferred embodiments, count by weight, there is the health product bag of regulating blood lipid action
Include：5-10 part perilla oil, 12-60 part Radix Oenotherae erythrosepalae oil, 10-40 part Fructus Rosae Normalis seed oil, 1-1.5 part Phosphatidylserine and 1-1.5
Part plant sterol.
The present invention proposes a kind of preparation method of the health product with regulating blood lipid action, and it comprises the following steps：
Prepare raw material by weight：Health-care oil 17-70 part, Fructus Rosae Normalis seed oil 10-40 part；Wherein, health-care oil includes Folium Perillae
In oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, granada seed oil at least two；
Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at a temperature of less than 25 DEG C, and stirs 15-60min and obtain health care
Compound oil.
Further, in present pre-ferred embodiments, using maltodextrin as cladding soluble in water as aqueous phase, will
Aqueous phase and health-care oil are mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder.
Further, in present pre-ferred embodiments, compound fat acid powder and plant extract or phospholipid are added
Thing mixes, and makes granule, tablet or capsule.
The beneficial effect of the embodiment of the present invention is：The health product with regulating blood lipid action provided in an embodiment of the present invention with
The high perilla oil of alpha-linolenic acid content, Semen Lini oil and the vegetable oil such as the higher Radix Oenotherae erythrosepalae oil of gamma -linolenic acid content, borage oil
It is mixed and made into alpha-linolenic acid：Gamma-Linolenic acid=1：1 health-care oil, then health-care oil and Fructus Rosae Normalis seed oil are mixed and made into unsaturated lipid
Fat acid n-6：N-3=4：1 health care compound oil, its composition proportion rationally, want by the absorption meeting human body for unsaturated fatty acid
Ask.The invention also discloses the preparation method of above-mentioned health product, and by embedding techniqueses, above-mentioned health product are prepared into compound
The preparation method of fatty acid powder, improves the stability of product and mobility so as to can preferably enter with other pressed powders
Row compounds to strengthen its effect：Compound with the phospholipid additive such as Phosphatidylserine, plant sterol, product can be strengthened and adjust blood
The function of fat；Compound with plant extracts such as Ginkgo Biloba Extract, oat peptide, bitter gourd polypeptides, blood sugar lowering, blood fat reducing can be produced
Synergism, three-hypers crowd preferably.Adopting folk prescription or several plant compared to other auxiliary blood fat-reducing products on the market more
Oil combines, and this product has balanced in nutrition, can meet the feature of the demand of different crowd, and on regulating blood lipid action, effect shows
Write, and process is simple environmental protection, reduce unsaturated fatty acid decomposition and the loss probability in preparation process.
Specific embodiment
Purpose, technical scheme and advantage for making the embodiment of the present invention are clearer, below will be in the embodiment of the present invention
Technical scheme be clearly and completely described.In embodiment, unreceipted actual conditions person, builds according to normal condition or manufacturer
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, being can be by the commercially available conventional product bought and obtain
Product.
Below to the embodiment of the present invention there are the health product of regulating blood lipid action and preparation method is specifically described.
The embodiment of the present invention provides a kind of health product with regulating blood lipid action, counts by weight, it includes：17-
70 parts of health-care oils, 10-40 part Fructus Rosae Normalis seed oil；Wherein, health-care oil include perilla oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil,
In granada seed oil at least two.
The health product with regulating blood lipid action that the present embodiment provides are the unsaturated fatty acids according to needed by human body
Proportion research obtains, from the higher perilla oil of linolenic acid content, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, granada seed oil
At least two with Fructus Rosae Normalis seed oil be mixed in proportion so as to get have regulating blood lipid action health-care product be rich in n-3 not
Satisfied fatty acid, and reach alpha-linolenic acid：Gamma-Linolenic acid=1:1, n-6 unsaturated fatty acid (gamma-Linolenic acid, linoleic acid)：n-
3 unsaturated fatty acids (alpha-linolenic acid)=4:1 preferable proportioning, to meet the demand of human body, makes this have regulating blood lipid action
Health product have functions that enhance immunity and adjust blood fat.
Preferably, have regulating blood lipid action health product count by weight including：5-10 part perilla oil, 12-60 part
Radix Oenotherae erythrosepalae oil, 10-40 part Fructus Rosae Normalis seed oil.
Perilla oil from proper ratio and Radix Oenotherae erythrosepalae oil are mixed with Fructus Rosae Normalis seed oil, not only have suitable linoleic acid：Sub-
Fiber crops acid proportioning, has preferable abnormal smells from the patient and mouthfeel simultaneously, and suitable hyperpietic uses.
In above-mentioned raw materials：Perilla oil is the oils and fatss being obtained for waste with Folium Perillae seed, Folium Perillae [Perilla
Frutescens (L.) Britt.] it is Labiatae annual herb plant, it is a kind of natural medicine food dual purpose plant.Perilla oil is rich
Containing multiple unsaturated fatty acids, particularly it contains the alpha-linolenic acid of 50%-60% (α-Linolenic acid) and 15% left side
Right linoleic acid (Linoleic Acid), alpha-linolenic acid is the necessary fatty acid that human body itself can not synthesize, can only be by taking the photograph in vitro
Enter, it has functions that to promote brain development and nourishing the brain and improving intelligence.Long-term taking perilla oil can adjust blood pressure and the blood fat of human body,
Reduce cholesterol, atherosclerosis, inhibition thrombosis, reduce the outbreak probability of cerebral thrombosiss and cardiovascular diseasess；In addition
Perilla oil also has enhancing immune function of human body, anti-inflammatory, antibacterial, adjusts organism metabolism, delays body aging health care skin and fat-reducing
Effect.Compared with bathypelagic fish oil, perilla oil not only be rich in DHA (docosahexenoic acid) and EPA (eicosapentaenoic acid) (α-
Linolenic acid is converted into DHA and EPA in human body), also do not contain cholesterol simultaneously, be a kind of healthy, safe to there is regulation blood fat
The health product of effect and healthy food material.
Semen Lini oil is to be produced the oils and fatss obtaining by Semen Lini, and Semen Lini (flaxseed), also known as flaxseed, is flax family (Linaceae)
The seed of annual or herbaceos perennial Caulis et Folium Lini of linum.Semen Lini oil contain 50% about alpha-linolenic acid and
The linoleic acid of 15-25%, can be very good to be used in mixed way with perilla oil, to reach suitable linoleic acid and linolenic proportioning,
Thus meeting the demand of human body.Semen Lini oil also contains the up to flavonoidss of 23mg/100g and abundant Vitamin E,
Make it have blood fat reducing, atherosclerosiss and antioxidative effect.
Radix Oenotherae erythrosepalae oil is to be produced the oils and fatss obtaining by evening primrose seed, and Radix Oenotherae erythrosepalae (Oenothera biennis) is Folium Salicis Babylonicae
A kind under dish section Oenothera.Radix Oenotherae erythrosepalae oil contains 70% linoleic acid and the gamma-Linolenic acid (Gamma of 10-20%
Linolenic Acid), gamma-Linolenic acid has anti-inflammatory, fall thrombosis and antiatherogenic effect, and it is that human body is musted
Must fatty acid, have significant good effect to the disease-resistant defying age of body, gamma-Linolenic acid can be with no esterification in human body
Presented in or participate in the constituent of cholesterol, triglyceride and phospholipid in esterified form, be the important set of cell membrane
Point.
10 borage oils are to be produced the oils and fatss obtaining by borage seed, and it contains 10% Palmic acid, 5.1% Hard Fat
γ-the linolenic acid of acid, 20.3% Oleic acid, 37.5% linoleic acid and 19.4% and 4.1% the fatty acid such as arachidic acid,
The content of wherein unsaturated fatty acid is up to more than 75%.Gamma -linolenic acid content in borage oil is very high, has and significantly prevents
Control cardiovascular disease, diabetes, cancer effect, there is the effects such as treatment dermatosiss, defying age, the liver protecting simultaneously.
Granada seed oil is to be produced the oils and fatss obtaining by Semen Granati.Granada seed oil mainly includes punicic acid, linolenic acid, sub- oil
Six kinds of fatty acids such as acid, Oleic acid, Palmic acid, stearic acid, the content of wherein punicic acid accounts for 86%, makes granada seed oil have antioxygen
Effect of change, anti-inflammatory, antithrombotic and slow down aging.
Fructus Rosae Normalis seed oil is to produce, by Fructus Rosae Normalis seed, the oils and fatss obtaining.Fructus Rosae Normalis (Rose Roxburghii Tratt) are Rosaceaes
Rosa perennial fallen leaves bush, is a kind of natural medicine food dual purpose plant.The main component of Fructus Rosae Normalis seed oil is 60-70%
Linoleic acid, 20% about linolenic acid, 10% about Oleic acid and other fatty acids, Fructus Rosae Normalis seed oil has regulation body and exempts from
The effects such as epidemic disease function, slow down aging, atherosclerosiss, antitumor.
Further, in present pre-ferred embodiments, count by weight, this has the health product of regulating blood lipid action
Including 3-6 part plant extract, plant extract includes Ginkgo Biloba Extract, bitter gourd polypeptide, at least one in oat peptide.Tool
Body ground, the health product with regulating blood lipid action include：5-10 part perilla oil, 12-60 part Radix Oenotherae erythrosepalae oil, 10-40 part Fructus Rosae Normalis seed
Oil, 1-3 part oat peptide, 1-3 part bitter gourd polypeptide and 1-3 part Ginkgo Biloba Extract.
Wherein, Ginkgo Biloba Extract (Ginkgo biloba P.E.) is to extract, for raw material, the product obtaining with Folium Ginkgo.
Ginkgo Biloba Extract can mitigate cholesterolemia, triacylglycerol, the adverse effect to human body for the very low density lipoprotein (VLDL) simultaneously, and drops
Hypolipemia, improves microcirculation, anticoagulant, has good hypertension therapeutic effect.Ginkgo Biloba Extract can also simultaneously facilitate
The circulation of brain and body limbs.Research shows, Ginkgo Biloba Extract can suppress a kind of and be referred to as platelet activating factor (PAF)
Material, PAF be a kind of from cell release medium, it can lead to platelet aggregation (accumulation) together, the PAF of high-load
Neural cell injury can be led to, central nervous system's blood flow reduces, inflammation, and bronchoconstriction are closely similar with free radical,
High PAF level also results in aging simultaneously.Bilobalide in Ginkgo Biloba Extract and bilobalide can be in ischemia (in-vivo tissues
Lacking oxygen) in period, the neurocyte of protection central nervous system is injury-free, and this function has auxiliary treatment to paralytic
Effect.In addition to suppression thrombocyte adhesiveness, Semen Ginkgo extrac can also adjust tension force and the elastic force of blood vessel, makes blood circulation more
Effective percentage.
Bitter gourd polypeptide is to extract the product obtaining from bitter melon seed.Bitter gourd polypeptide is a kind of safety, lasting, health, reliability
Blood sugar lowering material, its mainly by activate insulin, activation Insulin receptor INSR, improve insulin effective rate of utilization adjust blood
Sugar, thus realizing adjusting the purpose of blood glucose, and being free from side effects, can effectively reduce blood glucose and glycosuria.
Oat peptide is to extract the product obtaining from Herba bromi japonici.Multiple studies have shown that, oat peptide has preferable antioxygen
The property changed and alpha-amylase inhibition, alpha-amylase inhibition can delay or slow down carbohydrate in the digestion of intestinal and suction
Receive, suppress raising and reducing fasting glucose of level of postprandial blood sugar.
From what at least one in Ginkgo Biloba Extract, bitter gourd polypeptide, oat peptide was added in the present embodiment, there is tune
In the health product of section blood fat, this health product with regulating blood lipid action can be made to have the good work(adjusting blood fat
Effect, and can enhance immunity, improve brain blood circulation, improve sleep quality, the blood glucose of auxiliary adjustment user becomes simultaneously
Point.
Further, in present pre-ferred embodiments, count by weight, this has the health product of regulating blood lipid action
Including 1-3 part phospholipid additive, phospholipid additive includes at least one in Phosphatidylserine and plant sterol.Specifically,
The health product with regulating blood lipid action include：5-15 part perilla oil, 12-60 part Radix Oenotherae erythrosepalae oil, 10-40 part Fructus Rosae Normalis seed oil, 1-
1.5 parts of Phosphatidylserine and 1-1.5 part plant sterol.
Wherein, Phosphatidylserine (Phosphatidylserine) is the ingredient of cell membrane phospholipid.Phosphatidyl silk
Propylhomoserin can improve memory and cerebrum ischemia anaerobic condition, the aging of suppression brain, adjust blood fat, alleviate stress and body
Fatigue, Phosphatidylserine can improve the cytothesiss ability of user, improves brain oxygen supply ability.
Plant sterol is the product obtaining through physical purification from corn and soybean, its have be of high nutritive value, physiology live
The strong feature of property.Plant sterol has katabolism, the suppression cholesterol that suppression human body to the absorption of cholesterol, promotes cholesterol
The effect such as biochemical synthesis, thus reducing the risk that cholesterol reduces cardiovascular diseasess, it also has stronger antiinflammatory action simultaneously.
It is added with phospholipid additive in the health product have regulating blood lipid action, can improve further with regulation blood
The health product of fat effect adjust blood fat and blood pressure, reduce cholesterol, improve effect of human body immunity, reduce full in oils and fatss
With the adverse effect to human body for the fatty acid.
Present embodiments provide a kind of preparation method of the health product with regulating blood lipid action, comprise the following steps：
Count by weight, prepare raw material：Health-care oil 17-70 part, Fructus Rosae Normalis seed oil 10-40 part；Wherein, health-care oil includes purple
In Soviet Union's oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, granada seed oil at least two；
Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at a temperature of less than 25 DEG C, and stirs 15-60min and obtain health care
Compound oil.
Further, in present pre-ferred embodiments, using maltodextrin as cladding soluble in water as aqueous phase, will
Aqueous phase and health care compound oil are mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder.
Further, in present pre-ferred embodiments, by health care fatty acid powder and plant extract blood sugar lowering additive
And/or phospholipid additives mixed, make granule, tablet or capsule.
In the preparation method of the health product with regulating blood lipid action that the present embodiment provides, perilla oil, Semen Lini oil, the moon
See that grass oil, borage oil and granada seed oil are all obtained using the cold rolling legal system of low temperature, Fructus Rosae Normalis seed oil adopts supercritical CO2Extraction legal system
?.
The preparation method of the health product that the present embodiment provides, using embedding process, improves stability, the flowing of health product
Property；Solve the problems, such as easily to be layered when oil and solid ingredient mixing, uneven so that oil component easily with other compositions again
It is configured to the health product of solid-state.
With reference to embodiments the feature and performance of the present invention is described in further detail.
Embodiment 1
Embodiment 1 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 120g Radix Oenotherae erythrosepalae
Oil, 100g Fructus Rosae Normalis seed oil.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil 20
It is mixed and stirred for 45min at DEG C, make health-care oil；Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at 20 DEG C, and stirs
20min obtains health care compound oil.
Embodiment 2
Embodiment 2 provides a kind of health product with regulating blood lipid action, and it includes, and 100g perilla oil, the 600g month see
Grass oil, Fructus Rosae Normalis seed oil 100g.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil 20
It is mixed and stirred for 40min at DEG C, make health-care oil；Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at 20 DEG C, and stirs
20min obtains health care compound oil.
Embodiment 3
Embodiment 3 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 250g Radix Oenotherae erythrosepalae
Oil, 100g Fructus Rosae Normalis seed oil.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil 20
It is mixed and stirred for 45min at DEG C, make health-care oil；Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at 20 DEG C, and stirs
20min obtains health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, aqueous phase is mixed with health care compound oil
Close and form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder.
Embodiment 4
Embodiment 4 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 120g Radix Oenotherae erythrosepalae
Oil, 100g Fructus Rosae Normalis seed oil and 30g Ginkgo Biloba Extract.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil 20
It is mixed and stirred for 45min at DEG C, make health-care oil；Health-care oil is mixed in proportion with Fructus Rosae Normalis seed oil at 20 DEG C, and stirs
20min obtains health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, aqueous phase is mixed with health care compound oil
Close formed emulsifying liquid, by emulsifying liquid through spraying, be dried be obtained health care fatty acid powder, by health care fatty acid powder with
Ginkgo Biloba Extract mixes, and makes granule.
Embodiment 5
Embodiment 5 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 150g Radix Oenotherae erythrosepalae
Oil, 50g Semen Lini oil, 300g Fructus Rosae Normalis seed oil and 30g bitter gourd polypeptide.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, Caulis et Folium Lini
Seed oil is mixed and stirred for 45min at 20 DEG C, makes health-care oil；Health-care oil is mixed in proportion at 20 DEG C with Fructus Rosae Normalis seed oil,
And stir 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, aqueous phase is multiple with health care
Close oil and be mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, by health care fatty acid
Powder is mixed with bitter gourd polypeptide, makes capsule.
Embodiment 6
Embodiment 6 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 200g Radix Oenotherae erythrosepalae
Oil, 50g borage oil, 300g Fructus Rosae Normalis seed oil, 10g Ginkgo Biloba Extract, 20g oat peptide.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, coloured glaze
Lettuce oil is mixed and stirred for 45min at 20 DEG C, makes health-care oil；Health-care oil is mixed in proportion at 20 DEG C with Fructus Rosae Normalis seed oil,
And stir 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, aqueous phase is multiple with health care
Close oil and be mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, by health care fatty acid
Powder is mixed with Ginkgo Biloba Extract and oat peptide, makes tablet.
Embodiment 7
Embodiment 7 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 200g Radix Oenotherae erythrosepalae
Oil, 50g granada seed oil, 100g Fructus Rosae Normalis seed oil, 10g phospholipid additive.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, Punica granatum L.
Seed oil is mixed and stirred for 45min at 20 DEG C, makes health-care oil；Health-care oil is mixed in proportion at 20 DEG C with Fructus Rosae Normalis seed oil,
And stir 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, aqueous phase is multiple with health care
Close oil and be mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, by health care fatty acid
Powder and phospholipid additives mixed, make tablet.
Embodiment 8
Embodiment 8 provides a kind of health product with regulating blood lipid action, and it includes, 60g perilla oil, 180g Radix Oenotherae erythrosepalae
Oil, 30g granada seed oil, 30g borage oil, 100g Fructus Rosae Normalis seed oil, 15g plant sterol.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, Punica granatum L.
Seed oil, borage oil are mixed and stirred for 45min at 20 DEG C, make health-care oil；Health-care oil is pressed at 20 DEG C with Fructus Rosae Normalis seed oil
Ratio mixes, and stirs 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, by water
It is mixed to form emulsifying liquid with health care compound oil, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, will
Health care fatty acid powder is mixed with plant sterol, makes capsule.
Embodiment 9
Embodiment 9 provides a kind of health product with regulating blood lipid action, and it includes, 50g perilla oil, 180g Radix Oenotherae erythrosepalae
Oil, 30g Semen Lini oil, 30g borage oil, 100g Fructus Rosae Normalis seed oil, 15g Phosphatidylserine, 15g plant sterol.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, Caulis et Folium Lini
Seed oil, borage oil are mixed and stirred for 45min at 20 DEG C, make health-care oil；Health-care oil is pressed at 20 DEG C with Fructus Rosae Normalis seed oil
Ratio mixes, and stirs 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, by water
It is mixed to form emulsifying liquid with health care compound oil, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, will
Health care fatty acid powder is mixed with Phosphatidylserine and plant sterol, makes capsule.
Embodiment 10
Embodiment 10 provides a kind of health product with regulating blood lipid action, and it includes, and 50g perilla oil, the 180g month see
Careless oil, 30g borage oil, 30g Semen Lini oil, 30g granada seed oil, 100g Fructus Rosae Normalis seed oil, 20g Ginkgo Biloba Extract, 20g Fructus Momordicae charantiae
Polypeptide, 20g oat peptide, 15g Phosphatidylserine, 15g plant sterol.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, coloured glaze
Lettuce oil, Semen Lini oil, granada seed oil are mixed and stirred for 45min at 20 DEG C, make health-care oil；Health-care oil is existed with Fructus Rosae Normalis seed oil
Be mixed in proportion at 20 DEG C, and stir 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as water
Phase, aqueous phase and health care compound oil are mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid
Powder, health care fatty acid powder is mixed with Ginkgo Biloba Extract, bitter gourd polypeptide, oat peptide, Phosphatidylserine and plant sterol
Close, make capsule.
Embodiment 11
Embodiment 11 provides a kind of health product with regulating blood lipid action, and it includes, and 50g perilla oil, the 180g month see
Careless oil, 30g borage oil, 30g Semen Lini oil, 30g granada seed oil, 100g Fructus Rosae Normalis seed oil, 20g Ginkgo Biloba Extract, 20g Herba bromi japonici
Peptide, 10g Phosphatidylserine.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, coloured glaze
Lettuce oil, Semen Lini oil, granada seed oil are mixed and stirred for 45min at 20 DEG C, make health-care oil；Health-care oil is existed with Fructus Rosae Normalis seed oil
Be mixed in proportion at 20 DEG C, and stir 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as water
Phase, aqueous phase and health care compound oil are mixed to form emulsifying liquid, by emulsifying liquid through spraying, dry prepared health care fatty acid
Powder, health care fatty acid powder is mixed with Ginkgo Biloba Extract, oat peptide, Phosphatidylserine, makes tablet.
Embodiment 12
Embodiment 12 provides a kind of health product with regulating blood lipid action, and it includes, and 50g perilla oil, the 200g month see
Careless oil, 30g Semen Lini oil, 30g granada seed oil, 400g Fructus Rosae Normalis seed oil, 20g Ginkgo Biloba Extract, 20g oat peptide, 10g phosphatidyl
Serine.
The preparation method of the above-mentioned health product with regulating blood lipid action is：By the perilla oil preparing, Radix Oenotherae erythrosepalae oil, Caulis et Folium Lini
Seed oil, granada seed oil are mixed and stirred for 45min at 20 DEG C, make health-care oil；Health-care oil is pressed at 20 DEG C with Fructus Rosae Normalis seed oil
Ratio mixes, and stirs 20min and obtain health care compound oil, using maltodextrin as cladding soluble in water as aqueous phase, by water
It is mixed to form emulsifying liquid with health care compound oil, by emulsifying liquid through spraying, dry prepared health care fatty acid powder, will
Health care fatty acid powder is mixed with Ginkgo Biloba Extract, oat peptide, Phosphatidylserine, makes granule.
According to this technological process, the health-care oil active constituent content producing and quality are all very stable.Through authoritative department safety
And function test, result shows, this health product safety non-toxic, has the health-care effect of auxiliary blood fat reducing.Concrete content of the test with
Result is as follows：
1. safety testing
The toxicity safety test in the I and II stage of health care compound oil of embodiment 1 preparation shows：This product safety is nontoxic.
Jiangsu Prov. Disease Preventing and Controlling Center shows to I the and II stage toxicity safety test of this health product：
1.1 acute toxicity test in mice, male and female its mouse oral MTD value is all higher than 21500mg/kgb.wt., according to acute warp
Mouth toxicity grading standard, this sample belongs to nontoxic level.
1.2Ames test：This sample does not all detect to standard testing bacterium TA97, TA98, TA100 and TA102 and significantly lures
Become activity.
1.3 mouse marrow cell micro nuclear test：Dosage reaches 10000mg/kgb.wt, does not detect to male and female bone marrow cells in mice
Micronucleus has mutagenic action.
1.4 mouse inbred strain：Dosage reaches 10000mg/kgb.wt, does not detect the heredity poison to male mice sperm
Property.
Therefore, this health product does not have teratogenesis, mutagenesis and carcinogenecity.
1.5 30 days feeding trials：Sample (is respectively equivalent to human body to push away with 1670,3330 and 5000mg/kgb.wt dosage
Recommend intake 33.3mg/kgBW 50,100 and 150 times), feed rat 30 days, the ordinary circumstance of three dosage group animals, body
The when high dose group histopathology inspection of weight, food-intake, food utilization, hematology, blood biochemical analysis, organ weights, dirty body
Look into compare with matched group and be showed no significant difference.
2. auxiliary blood fat reducing test
2.1 experimental animal：Take male SD rat 40, be randomly divided into high fat matched group and basic, normal, high three agent by TC value
Amount group, every group 10, single cage is raised, and freely absorbs high lipid food.
2.2 test method：Weigh sample 1.665g, 3.330g, 6.660g respectively, plus salad oil, to 100ml, mixes, point
Not basic, normal, high three dosage groups gavage liquid.Gavage capacity is 10ml/kgBW, and continuous gavage 30d takes tail blood, measures blood
Clear TC, serum TG and Serum HDL-C level.
2.3 data statistics processing methods：Using SAS statistical software to each experimental group number according to carrying out variance analyses, use
Dunnett ' st inspection carries out the comparison of each dosage group and high fat matched group.
2.4 result
2.4.1 during testing, the change of each group the weight of animals is shown in Table 1.
The impact (means standard deviation) to rat body weight (g) for this health product of table 1
From table 1, during test, between the weight of animals each group, there was no significant difference (P>0.05), each dosage group is big to testing
The body weight of Mus has no obvious impact.
2.4.2 the impact to Serum TC content is shown in Table 2.
The impact (means standard deviation) to Serum TC (mmol/L) for this health product of table 2
From table 2, the detected value of each group animal serum TC there was no significant difference (P before test>0.05).Compare with high fat
Group compares each dosage group all has reduction to Serum TC, middle and high two dosage groups there were significant differences (P<0.05).
2.4.3 the impact to rat blood serum TG content is shown in Table 3.
The impact (means standard deviation) to rat blood serum TG (mmol/L) for this health product of table 3
From table 3, the detected value of each group animal serum TG there was no significant difference (F=0.07, P before test>0.05).With
High fat matched group compares each dosage group all has reduction to rat blood serum TG, high dose group there were significant differences (P<0.05).
2.4.4 the impact to rat blood serum HDL-C content is shown in Table 4.
The impact (means standard deviation) to rat blood serum TG (mmol/L) for this health product of table 4
From table 4, the detected value of each group animal serum TG there was no significant difference (F=0.05, P before test>0.05).With
High fat matched group compares each dosage group all has rising to rat blood serum HDL-C, high dose group there were significant differences (P<0.05).
2.5 conclusion
Result shows that this sample has no significant effect to the body weight of experimental rat, and middle and high dosage has reduction experimental rat blood
The effect of clear T-CHOL, high dose has the effect reducing experimental rat serum triglycerides and improves experimental rat serum height
The effect of density lipoprotein-cholesterol.
According to《Function of health food assessment process and method of inspection specification》In " the auxiliary lipid-lowering function method of inspection "
The criterion of animal experiment, this sample has the effect of auxiliary lipid-lowering function.
3 human feeding trials
3.1 study subjects and packet：From embodiment 1 preparation health care compound oil as tested group.Matched group takes peace
Console agent, be shown in Table 5 and table 6 situations such as the clinical sex of patient chosen, age, blood lipid level
The sex of table 5 test-meal group and matched group, age, the ill time limit
| Group | Number of cases | Man | Masculinity proportion | Female | Female ratio | Mean age |
| Test-meal group | 52 | 27 | 51.9 | 25 | 48.1 | 53.2 |
| Matched group | 50 | 31 | 62 | 19 | 38 | 52.5 |
Table 6 test-meal group and the initial blood lipid level of matched group
| Group | Number of cases | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) |
| Test-meal group | 52 | 5.62 | 3.09 | 1.28 |
| Matched group | 50 | 5.52 | 2.89 | 1.31 |
Wherein：TC is serum total cholesterol content, mmol/L；TG is content of triglyceride, mmol/L；HDL-C is fat egg
White cholesterol level, mmol/L.
3.2 eating method：Matched group adopts placebo, and test-meal group patient presses 2 every time, and the method that 2 times a day eats this
Health product.The test-meal cycle is 30 days, and two groups of experimenters all keep life on ordinary days and dietary habit.
3.3 observation index：Observe experimenter's serum T-CHOL (TC), triglyceride (TG), high density lipoprotein gallbladder admittedly
Alcohol (HDL-C) level and situation of change.
3.4 criterion
Effectively：TC reduces>10%；TG reduces>15%；HDL-C rises>0.104mmol/L
Always effective：Above-mentioned three indexs are arbitrary effectively
Invalid：Not up to effective standard person
3.5 result
After 30 days, each group patient is carried out detecting serum total cholesterol content, the content of triglyceride obtaining 102 patients
As shown in table 7 with lipoprotein cholesterol changes of contents：
Two groups of patient TC, TG and HDL-C changes before and after table 7 test
Wherein serum total cholesterol (TC) and triglyceride (TG) amplitude of variation are reduction amplitude, and high density lipoprotein gallbladder is solid
Alcohol (HDL-C) amplitude of variation is ascensional range.
The contrast of 8 liang of group hyperlipemia test-meal effects of table
From table 8, the effective percentage of health product TC, TG to test-meal group patient is significantly better than that matched group.
From above-mentioned clinical trial, what the present invention provided has the health product of regulating blood lipid action for hyperlipemic patients
There is significant auxiliary curative effect, the serum total cholesterol (TC) of test-meal group patient and triglyceride (TG) content substantially reduce, its
The serum total cholesterol of middle test-meal group patient reduces percentage rate average out to 12.5%, and triglyceride reduces percentage rate average out to
21.6%, simultaneously all without exception to the blood of test-meal group patient, urine, feces routine examination regulating liver-QI, kidney function test, it follows that this
The health product that invention provides have good auxiliary lipid-lowering efficacy, are that the health care that a kind of suitable hyperlipemic patients use is produced
Product.
To sum up, what the present invention provided has the health product of regulating blood lipid action using suitable formula, effectively caters to
The demand of human body, can improve the health care of sleep, and improve memory, strengthen body immunity, adjust blood fat, prevention and auxiliary treatment painstaking effort
Pipe disease.
Embodiments described above is a part of embodiment of the present invention, rather than whole embodiments.The reality of the present invention
The detailed description applying example is not intended to limit the scope of claimed invention, but is merely representative of the selected enforcement of the present invention
Example.Based on the embodiment in the present invention, those of ordinary skill in the art are obtained under the premise of not making creative work
Every other embodiment, broadly falls into the scope of protection of the invention.
Claims (10)
1. it is characterised in that counting by weight, it includes a kind of health product with regulating blood lipid action：
Health-care oil 17-70 part；And
Fructus Rosae Normalis seed oil 10-40 part；
Wherein, described health-care oil include perilla oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, in granada seed oil at least two
Kind.
2. the health product with regulating blood lipid action according to claim 1 are it is characterised in that count by weight, its
Including：
Described perilla oil 5-10 part；
Described Radix Oenotherae erythrosepalae oil 12-60 part；And
Described Fructus Rosae Normalis seed oil 10-40 part.
3. the health product with regulating blood lipid action according to claim 1 are it is characterised in that described have regulation blood fat
The health product of effect also include 3-6 part plant extract, and described plant extract includes Ginkgo Biloba Extract, bitter gourd polypeptide, swallow
At least one in wheat peptide.
4. the health product with regulating blood lipid action according to claim 3 are it is characterised in that count by weight, its
Including：
5. the health product with regulating blood lipid action according to claim 1 are it is characterised in that described have regulation blood fat
The health product of effect also include 1-3 part phospholipid additive, and described phospholipid additive is included in Phosphatidylserine and plant sterol
At least one.
6. the health product with regulating blood lipid action according to claim 5 are it is characterised in that count by weight, its
Including：
7. the health product with regulating blood lipid action according to claim 1 preparation method it is characterised in that include with
Lower step：
Prepare raw material by weight：Health-care oil 17-70 part, Fructus Rosae Normalis seed oil 10-40 part；Wherein, described health-care oil includes Folium Perillae
In oil, Semen Lini oil, Radix Oenotherae erythrosepalae oil, borage oil, granada seed oil at least two；
Described health-care oil is mixed in proportion with described Fructus Rosae Normalis seed oil at a temperature of less than 25 DEG C, and stirs 15-60min and obtain
Health care compound oil.
8. the preparation method of the health product with regulating blood lipid action according to claim 7 is it is characterised in that by Fructus Hordei Germinatus
Described aqueous phase and described health care compound oil are mixed to form emulsifying liquid as cladding is soluble in water as aqueous phase by dextrin,
By described emulsifying liquid through spraying, prepared health care fatty acid powder is dried.
9. the preparation method of the health product with regulating blood lipid action according to claim 8 is it is characterised in that will be described
Compound fat acid powder and plant extract or phospholipid additives mixed, make granule, tablet or capsule.
10. any one of claim 1-6, there is the application on health food of the health product of regulating blood lipid action, its
It is characterised by, the described health product with regulating blood lipid action are prepared into the health food of prevention cardiovascular and cerebrovascular disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610851226.1A CN106418542A (en) | 2016-09-26 | 2016-09-26 | Health-care product having function of regulating blood lipids and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610851226.1A CN106418542A (en) | 2016-09-26 | 2016-09-26 | Health-care product having function of regulating blood lipids and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106418542A true CN106418542A (en) | 2017-02-22 |
Family
ID=58170160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610851226.1A Pending CN106418542A (en) | 2016-09-26 | 2016-09-26 | Health-care product having function of regulating blood lipids and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106418542A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107418722A (en) * | 2017-05-18 | 2017-12-01 | 毕节市中药产业发展办公室 | Use supercritical CO2Extract Rosa roxburghii seed oil |
| CN109924503A (en) * | 2019-04-01 | 2019-06-25 | 江苏启星生物科技有限公司 | A kind of functionality linseed oil compound powder and preparation method thereof |
| CN110679943A (en) * | 2019-10-25 | 2020-01-14 | 李玉保 | Bitter gourd polypeptide compound nutrient with weight-losing and lipid-lowering effects and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895393A (en) * | 2006-06-27 | 2007-01-17 | 吕海章 | Halth-care composition for regulating blood fat |
| CN101124928A (en) * | 2007-09-24 | 2008-02-20 | 张国浩 | Nutrition balanced mixed oil containing omega-3 polyunsaturated fatty acid and producing method thereof |
| CN101731579A (en) * | 2008-11-18 | 2010-06-16 | 冯峰 | Health-care food with function of assisting reducing blood fat and preparation method thereof |
| CN104256610A (en) * | 2014-10-11 | 2015-01-07 | 汤臣倍健股份有限公司 | Health care composition and soft capsule for assisting blood lipid reduction |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
-
2016
- 2016-09-26 CN CN201610851226.1A patent/CN106418542A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895393A (en) * | 2006-06-27 | 2007-01-17 | 吕海章 | Halth-care composition for regulating blood fat |
| CN101124928A (en) * | 2007-09-24 | 2008-02-20 | 张国浩 | Nutrition balanced mixed oil containing omega-3 polyunsaturated fatty acid and producing method thereof |
| CN101731579A (en) * | 2008-11-18 | 2010-06-16 | 冯峰 | Health-care food with function of assisting reducing blood fat and preparation method thereof |
| CN104256610A (en) * | 2014-10-11 | 2015-01-07 | 汤臣倍健股份有限公司 | Health care composition and soft capsule for assisting blood lipid reduction |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107418722A (en) * | 2017-05-18 | 2017-12-01 | 毕节市中药产业发展办公室 | Use supercritical CO2Extract Rosa roxburghii seed oil |
| CN109924503A (en) * | 2019-04-01 | 2019-06-25 | 江苏启星生物科技有限公司 | A kind of functionality linseed oil compound powder and preparation method thereof |
| CN110679943A (en) * | 2019-10-25 | 2020-01-14 | 李玉保 | Bitter gourd polypeptide compound nutrient with weight-losing and lipid-lowering effects and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141712B (en) | Compound feed for laying hens in egg producing period and preparation method of feed | |
| Ganorkar et al. | Flaxseed--a nutritional punch. | |
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN103444911A (en) | Medicinal and edible health care blending oil | |
| CN103355555A (en) | Feed for laying hen in egg-laying peak stage and preparation method thereof | |
| CN106962506A (en) | A kind of ready-mixed oil and preparation method thereof | |
| CN101919452B (en) | Compound oil health food | |
| CN104004583B (en) | Containing the natural health vegetables oil and its preparation method and application of linoleic acid plus linolenic acid | |
| CN102058631B (en) | Seabuckthorn leaf extract preparation and preparation method thereof | |
| CN106418542A (en) | Health-care product having function of regulating blood lipids and preparation method thereof | |
| CN101658210A (en) | Perilla sesame oil and preparation method as well as application thereof | |
| US10227547B2 (en) | Astragalus membranaceus seed raw oil, refined oil, preparation method therefor and use thereof | |
| CN101564180B (en) | Walnut total nutriment and soft capsule and health products containing same | |
| CN103250950A (en) | Full-nutritional food combination and preparation method thereof | |
| CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
| CN105941553A (en) | Cookie suitable for hypertensives to eat | |
| CN109652202A (en) | A kind of intelligence development safflower tea oil and preparation method thereof | |
| CN101496604A (en) | Nutrient foodstuffs with function for reducing blood fat and preparation method thereof | |
| CN103766507A (en) | Edible oil with health-care function | |
| CN104886272A (en) | Special dietary peony seed nutritional blend oil for middle-aged and elderly people | |
| CN103798596B (en) | Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases | |
| Chandra et al. | A Review On Application And Benefits Of Flax Seed (Linum Usitatissimmum L.) | |
| CN106433949A (en) | Low-acid-value Yunnan pine seed oil, preparation method and application thereof | |
| CN105267968A (en) | Natural medicine composition with weight reducing effect | |
| CN106491922B (en) | Traditional Chinese medicine formula medicine suitable for qi stagnation and turbid phlegm type hyperlipemia and capsule thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |